Invention Grant
- Patent Title: Compositions and methods for treating clostridium difficile infection
-
Application No.: US16317887Application Date: 2017-07-25
-
Publication No.: US10758591B2Publication Date: 2020-09-01
- Inventor: Alyse Longtin Frisbee , William A. Petri, Jr.
- Applicant: University of Virginia Patent Foundation
- Applicant Address: US VA Charlottesville
- Assignee: University of Virginia Patent Foundation
- Current Assignee: University of Virginia Patent Foundation
- Current Assignee Address: US VA Charlottesville
- Agency: Jenkins, Wilson, Taylor & Hunt, P.A.
- International Application: PCT/US2017/043651 WO 20170725
- International Announcement: WO2018/022575 WO 20180201
- Main IPC: A61K38/14
- IPC: A61K38/14 ; C07K14/54 ; A61K45/06 ; A61K38/20 ; A61P31/04 ; A61K31/4164 ; A61K39/395 ; A61P1/04 ; A61K31/7036 ; A61K31/426 ; A61K38/00 ; A61K31/437 ; A61K31/7042 ; A61K31/7048

Abstract:
Clostridium difficile infection is the leading cause of hospital acquired antibiotic-associated diarrhea in the US (Bartlett, in 2006). The increased prevalence of circulating C. difficile strains poses a significant health threat to US health care facilities. Strains expressing the toxin C. difficile Transferase (CDT), in addition to Toxins A and B (TcdA and TcdB), are more virulent and are associated with higher mortality rates (Bacci et al., 2011). We recently identified a protective role for eosinophils against C. difficile pathogenesis (Buonomo et al., 2016). We have also defined CDT's ability to increase host inflammation and suppress protective eosinophils through a TLR2 dependent mechanism (Cowardin et al., 2016). How CDT promotes virulence and eosinophil suppression via TLR2 is still under investigation. We employed a genome-wide microarray approach to reveal divergent transcriptional profiles between protected (TLR2−/−) and unprotected (WT) mice infected with either CDT expressing or CDT mutant strains of C. difficile. This work revealed novel host mediated TLR2-dependent inflammatory pathways to CDT. We provide an unbiased framework for understanding the host immune response to the binary toxin CDT produced by C. difficile and how TLR2 signaling enhances virulence.
Public/Granted literature
- US20190290732A1 COMPOSITIONS AND METHODS FOR TREATING CLOSTRIDIUM DIFFICILE INFECTION Public/Granted day:2019-09-26
Information query
IPC分类: